
News|Articles|February 1, 2007
February 2007 Oncology News International
Advertisement
Cover Story
- Pancreatic Ca Vaccine Extends Survival After Surgery
Focus on Lung Cancer
- BB-10901 Compound Delivers Potent Agent to CD56+ Tumors
- First-line Nab-paclitaxel Shows Efficacy in NSCLC Trials
Focus on Hematology
- High Response Rate for Lenalidomide Plus Melphalan and Prednisone in Newly Diagnosed Multiple Myeloma Patients
Cancer Care & Economics
- Billing Plans for Routine Care Essential When Patients Enroll in Clinical Trials
- RHIOs Allow Exchange of Electronic Info
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
3
Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer
4
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
5




















































